innovation. ​quality care. choice.
mission statement
-
VoyagerMed enables Doctors to access cutting edge stem cell, medical device and international clinical trials for their patients that are not available in the US through our white label online platform.
-
The enterprise model will enable Doctors to offer advanced procedures, such as stem cell, CE mark medical devices and others to retain cash paying patients who are seeking innovative medical options.
-
We will make it easy for them to go to our Cayman center, and other locations that we contract with, where the referring physician can also treat the patient offshore.
business model overview
1. Medical tourism where we bring Doctors and patients together for advanced medical treatment options outside the US.
2. Research and development of new stem cell technologies, medical devices and treatment options through clinical trials by our Doctors. We contract for a large percentage of any IP developed in our ecosystem.
3. Education through "hands on" CMEs that allow our Doctors to teach others the skills to use our innovative products and procedures.
MEDICAL TOURISM discovery
Medical Tourism for the best quality healthcare
Medical Tourism for beautiful destinations
MEDICAL TOURISM discovery
strategy
The first phase of the business will be to attract top Doctors from around the country in the fields of Orthopedic surgery and Plastic surgery.
We anticipate that our current Doctor network will enable this group to grow rapidly.
The second and third phases will include building out this network, inventing or improving upon current stem cell products, R&D and clinical trials as well as the educational component through CMEs.
The field of medicine has been one of the most dynamic and inventive endeavors in the history of mankind. ​ We help foster innovation and invention with an International Healthcare Exchange that brings Doctors and Patients together.

Our primary mission is to be the first international platform that will deliver Stem Cell treatment options, cutting edge medical device access and clinical trials to a segment of the population that would not otherwise have access to these treatments.
